2022
Toxicity Assessment of Mesoporous Silica Nanoparticles upon Intravenous Injection in Mice: Implications for Drug Delivery
MacCuaig W, Samykutty A, Foote J, Luo W, Filatenkov A, Li M, Houchen C, Grizzle W, McNally L. Toxicity Assessment of Mesoporous Silica Nanoparticles upon Intravenous Injection in Mice: Implications for Drug Delivery. Pharmaceutics 2022, 14: 969. PMID: 35631554, PMCID: PMC9148138, DOI: 10.3390/pharmaceutics14050969.Peer-Reviewed Original ResearchPre-existing lesionsIntravenous injectionChronic injectionsTreatment groupsBlood chemistryComplete blood count analysisStandard blood chemistryBlood count analysisMultiple intravenous injectionsModerate exacerbationsAdministered treatmentVascular conditionsMinor exacerbationsVital organsFurther evaluationTreatment of diseasesMinimal toxicityTranslational potentialNano-delivery systemsExacerbationFurther studiesInjectionLesionsMiceVivo toxicity
2016
Chronic miR‐29 antagonism promotes favorable plaque remodeling in atherosclerotic mice
Ulrich V, Rotllan N, Araldi E, Luciano A, Skroblin P, Abonnenc M, Perrotta P, Yin X, Bauer A, Leslie KL, Zhang P, Aryal B, Montgomery RL, Thum T, Martin K, Suarez Y, Mayr M, Fernandez-Hernando C, Sessa WC. Chronic miR‐29 antagonism promotes favorable plaque remodeling in atherosclerotic mice. EMBO Molecular Medicine 2016, 8: 643-653. PMID: 27137489, PMCID: PMC4888854, DOI: 10.15252/emmm.201506031.Peer-Reviewed Original ResearchConceptsPlaque morphologyReduced lesion sizeAcute myocardial infarctionAtherosclerotic mouse modelVulnerable atherosclerotic lesionsFibrous cap thicknessPlaque extracellular matrixChronic administrationExtracellular matrixAtherosclerotic miceMyocardial infarctionPlaque remodelingSolid organsAbnormal remodelingMouse modelAtherosclerotic lesionsAtherosclerotic plaquesBlood chemistryLesion sizeMiR-29Necrotic zoneLesionsPlaquesCap thicknessMiR-29 target genes
2010
Molecular Pharmacology and Antitumor Activity of PHT-427, a Novel Akt/Phosphatidylinositide-Dependent Protein Kinase 1 Pleckstrin Homology Domain Inhibitor
Meuillet EJ, Zuohe S, Lemos R, Ihle N, Kingston J, Watkins R, Moses SA, Zhang S, Du-Cuny L, Herbst R, Jacoby JJ, Zhou LL, Ahad AM, Mash EA, Kirkpatrick DL, Powis G. Molecular Pharmacology and Antitumor Activity of PHT-427, a Novel Akt/Phosphatidylinositide-Dependent Protein Kinase 1 Pleckstrin Homology Domain Inhibitor. Molecular Cancer Therapeutics 2010, 9: 706-717. PMID: 20197390, PMCID: PMC2837366, DOI: 10.1158/1535-7163.mct-09-0985.Peer-Reviewed Original ResearchMeSH Keywords3-Phosphoinositide-Dependent Protein KinasesAnimalsAntineoplastic AgentsFemaleHumansMiceMice, Inbred C57BLMice, NudeModels, BiologicalOncogene Protein v-aktProtein BindingProtein Interaction Domains and MotifsProtein Kinase InhibitorsProtein Serine-Threonine KinasesSulfonamidesThiadiazolesTumor Cells, CulturedXenograft Model Antitumor AssaysConceptsAntitumor activityTumor xenograftsNon-small cell lung cancerMolecular pharmacologyCell lung cancerAdditive antitumor activityHuman tumor xenograftsPHT-427K-ras mutant tumorsVivo antitumor activityLung cancerSensitive tumorsPIK3CA mutationsBreast cancerImmunodeficient miceBlood chemistryMutant tumorsCombination studiesResistant cellsMinimal toxicityWeight lossTumorsCancerCancer cellsAkt inhibition
2007
From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis
Lebwohl M, Bagel J, Gelfand J, Gladman D, Gordon K, Hsu S, Kalb R, Kimball A, Korman N, Krueger G, Mease P, Morison W, Paller A, Pariser D, Ritchlin C, Strober B, Van Voorhees A, Weinstein G, Young M, Horn L. From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis. Journal Of The American Academy Of Dermatology 2007, 58: 94-105. PMID: 17980456, DOI: 10.1016/j.jaad.2007.08.030.Peer-Reviewed Original ResearchConceptsLiver function testsBiologic therapyNational Psoriasis FoundationCD4 countAntinuclear antibodiesFunction testsPlatelet countPhysical examinationVaccination practicesTumor necrosis factor blockersNecrosis factor blockersTuberculin skin testTreatment of psoriasisBlood cell countEvidence-based studiesMedical boardsFactor blockersPsoriatic arthritisSkin testBlood countConsensus conferenceParticular therapyBlood chemistryPatientsLive vaccine
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply